High-density lipoprotein particles, coronary heart disease, and niacin.
The use of statins in patients with high risk for cardiovascular disease (CVD) has resulted in a 30-40% decrease in clinical events in the last couple of decades. However, despite of a marked reduction (up to 60%) in LDL-C, about 30% of patients continue to have CVD events. This high residual risk in statin-treated patients initiated the search for new ways to reduce CVD risk. HDL is the next logical target. Epidemiological and cross-sectional studies identified low HDL-C level as an independent risk for CVD. Based on the Framingham Heart Study data, HDL-C <35 mg/dl was established an independent risk factor and HDL-C >60 mg/dl as protective.(3) Presently the cut point is <40 mg/dl for men and <50 mg/dl for women.
Lipid Metabolism Laboratory, Tufts University, 711 Washington Street, Boston, MA 02111, USA. bela.asztalos@tufts.edu
Bela F
BF
Asztalos
D016632:Apolipoprotein A-I / Q000737:chemistry / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood / Q000378:metabolism*; D009525:Niacin / Q000627:therapeutic use*; D012307:Risk Factors
D016632:Apolipoprotein A-I; D053480:Cholesterol Ester Transfer Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D009525:Niacin